Skip to main content

Aventura • South Florida

Ketamine in the News

Selected recent coverage and research about ketamine therapy.

¡Hablamos Español!

Ketamine in the News

Recent articles and stories highlighting the potential benefits of ketamine therapy.

HFB Podcast · 2026

Dr. Jacob Silverstone on Ketamine Therapy and Trauma Healing

Dr. Jacob Silverstone discusses ketamine therapy, trauma healing, and the approach at Rewired Ketamine in Aventura.

International Business Journal · October 15, 2026

Ketamine Clinic in Aventura Reports 3,000 Infusions and 85% Success Rate for Treatment-Resistant Conditions

International Business Journal profiled Rewired Ketamine’s Aventura clinic, noting more than 3,000 guided infusions and the clinic’s reported outcomes for patients who had not found relief with standard treatments. Locally owned, Spanish-speaking, in-clinic care.

Woman’s Week · October 15, 2026

Rewired Ketamine Racks Up 3,000 Infusions, Earned REMS Status

Woman’s Week covered Rewired Ketamine’s Aventura practice, highlighting 3,000+ infusions and REMS certification for Spravato. The piece notes in-clinic IV ketamine and esketamine options with integration support.

Neuropsychiatric Disease and Treatment · September 2025

Spravato for Treatment-Resistant Depression: A 2025 Review

Raza and colleagues reviewed intranasal esketamine (Spravato) for major depression and treatment-resistant depression. Trials such as TRANSFORM-2, SUSTAIN-1, and ASPIRE are cited for rapid antidepressant effects, often within hours, through NMDA receptor antagonism. Spravato is given in clinic under REMS. Reported effects include dissociation and blood pressure changes. A 2025 review reported lower rates of sexual side effects than many SSRIs; individual results vary. This is a research summary, not a treatment claim.

Revista Veritas · September 30, 2026

The NMDA Receptor in Opioid-Induced Hyperalgesia

A narrative review of how opioid exposure can increase pain sensitivity, and why ketamine and magnesium are the agents most directly tied to the NMDA receptor in perioperative research. It supports an opioid-sparing role in acute surgical pain. It is not a depression-treatment claim.

SciTechDaily · September 21, 2026

Scientists Discover a Brain Signal Linked to Ketamine’s Antidepressant Effects

SciTechDaily covers Texas A&M research in Translational Psychiatry. Veterans over 55 received a single ketamine infusion. EEG patterns kept changing over the following week. Greater information-sharing in brain signals at 24 hours was linked to more symptom relief by day seven. Early work on possible response markers — not a clinic treatment claim.

Reuters · September 15, 2026

Psychedelic Therapies Cited by Trump: What You Need to Know

Reuters reviews the clinical and regulatory landscape after an FDA public meeting on psychedelic therapies. Most remain Schedule I in the U.S. Trials are furthest along for severe depression and PTSD. The piece also notes Spravato (esketamine) is FDA-approved for treatment-resistant depression, and that ketamine is authorized as an anesthetic and sometimes used off-label for depression. Research is moving quickly; results and access still vary.

Nature Structural & Molecular Biology · 2026

New Insights into NMDA Receptor Structure and Function

A recent paper in Nature Structural & Molecular Biology advances our understanding of NMDA receptor biology — the same receptor system central to how ketamine works in the brain.

CNN · September 2025

Can the party drug ketamine be a mental health breakthrough? It was for me

A personal account of how ketamine therapy helped with long-standing anxiety and depression.

Us Weekly · 2026

What Celebrities and Doctors Have Said About Ketamine Use

Celebrities including Chrissy Teigen, Elon Musk, Molly O’Connell and others share their experiences with ketamine therapy.

DAV · 2025

Green Beret turns to ketamine to heal invisible wounds

A Green Beret discusses how ketamine helped him recover from PTSD and reclaim daily life.

Stanford Medicine · May 2026

Drug combo is the first to prolong ketamine’s antisuicide effects

New research from Stanford shows a promising way to extend ketamine’s anti-suicidal benefits.

Billboard · July 2026

Why Grimes, Melissa Etheridge & More Artists Push Psychedelic Therapy

Musicians and artists openly discuss the potential of ketamine and other psychedelic-assisted therapies.

Rutgers University · 2024

Ketamine May Fight Chronic Fatigue, Study Suggests

New research from Rutgers suggests ketamine may help reduce symptoms of chronic fatigue.

News-Medical.net · July 2026

Ketamine Boosts Neuroplasticity Through Microglia in Female Brains

New research shows ketamine may increase neuroplasticity in female brains by activating microglia, highlighting important sex differences that could help refine future depression treatments.

Medscape News Canada · August 2026

Ketamine and Psychotherapy: A Winning Combination?

A small Toronto pilot study and the “Montreal model” explore pairing ketamine with weekly psychotherapy. Early findings suggest the combination may support neuropathic pain and help extend ketamine’s short-lived mental-health benefits.

Futurity · Texas A&M University · September 2026

How Ketamine Reshapes Brain Activity in Older Adults

Texas A&M researchers found time-specific brain-activity patterns after ketamine in older adults with treatment-resistant depression. Different information-organization patterns appeared at 1 hour, 24 hours, and 7 days. Greater brain-wide information sharing at 24 hours was linked to better symptom improvement at day 7. The work is aimed at possible biomarkers of response in late-life depression — not a guarantee of outcome.

Ready to take the next step?

Book a free consultation. No pressure — just honest answers and a clear path forward.

Book Free Consultation